Results for this period
Full year1 April 2025–31 March 2026Non-consolidated (standalone)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Revenue from antibody research support was ¥40.270 million, up 65.4% year on year, due to orders for larger projects and an increase in the number of projects. Revenue from antibody and reagent sales was ¥95.237 million, down 0.8% year on year. Selling, general and administrative expenses were ¥861.120 million, including ¥573.593 million in research and development expenses, down 7.5% year on year. Non-operating income included ¥53.311 million in subsidy income and foreign exchange gains, while an impairment loss of ¥37.260 million was recorded as an extraordinary loss for the fiscal year.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥135 million (YoY +12.6%) |
| Operating profit | ¥-744 million |
| Ordinary income | ¥-678 million |
| Profit attributable to owners of the parent | ¥-718 million |
| Net income per share | (¥48.17) |
| Operating Margin | △549.8％ |
| Equity ratio | End of the current fiscal period 70.1％ / End of previous period 74.4％ |
| Total assets | ¥1,623 million |
| Net assets | ¥1,217 million |
| Cash flows from operating activities | ¥-653 million |
| Cash flows from investing activities | ¥-10 million |
| Cash flows from financing activities | ¥497 million |
| Cash and cash equivalents at end of period | ¥1,515 million |
| Full-year earnings forecast | Net Sales Not disclosed / Operating profit Not disclosed / Ordinary income Not disclosed / Net income Not disclosed / Reason Not disclosed because a reasonable earnings forecast is difficult to prepare |
| Annual Dividend Forecast | ¥0 → ¥0（0.0%） |
| Depreciation and amortization | ¥382 thousand |
| Impairment loss | ¥37,260 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Not disclosed / Extraordinary loss Impairment Losses ¥37,260 thousand |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate Yes / Restatement No |
| Material subsequent events | At a meeting of the Board of Directors held on 15 April 2026, the company resolved to issue 1,237 stock acquisition rights as stock compensation-type stock options for executive officers and employees. The allocation was finalized on 1 May 2026, and stock compensation expenses of ¥25.701 million are scheduled to be recognized over the vesting period. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Institutional investors and analysts |
| Issued Shares at Period-End | 16,999,600 shares |
| Treasury Shares at Period-End | 90 shares |
| Factors Behind Changes in Business Performance | Revenue from antibody research support was ¥40.270 million, up 65.4% year on year, due to orders for larger projects and an increase in the number of projects. Revenue from antibody and reagent sales was ¥95.237 million, down 0.8% year on year. Selling, general and administrative expenses were ¥861.120 million, including ¥573.593 million in research and development expenses, down 7.5% year on year. Non-operating income included ¥53.311 million in subsidy income and foreign exchange gains, while an impairment loss of ¥37.260 million was recorded as an extraordinary loss for the fiscal year. |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue from antibody research support increased due to orders for larger projects and an increase in the number of projects. Selling, general and administrative expenses, including research and development expenses, decreased 7.5% year on year. The ordinary loss narrowed, partly due to non-operating income including subsidy income, interest income and foreign exchange gains. Although the company recorded an impairment loss of ¥37.260 million, the net loss decreased from the previous fiscal year.